Focus on Inhaled β2-Agonists: Efficacy, Safety, and Patient Preference

Pharmacotherapy

Volumn 24, Issue 5 II, 2004, Pages

  Pleasants II, Roy A ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CAMPBELL UNIVERSITY   (United States)

Author keywords

2 agonist; Albuterol; FEV1; Forced expiratory volume in 1 second; Heliox; Levalbuterol; Metered dose inhaler; Nebulization

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HELIOX; IPRATROPIUM BROMIDE; LEVALBUTEROL; LONG ACTING DRUG; ORCIPRENALINE; PIRBUTEROL; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG;

ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERANCE; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; HYPOKALEMIA; LEG CRAMP; METERED DOSE INHALER; MUCOCILIARY CLEARANCE; NEBULIZATION; TACHYCARDIA; TREMOR; UNITED STATES;

EID: 2342619532     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.7.44S.34755     Document Type: Conference Paper

References (55)

1. Knoell DL, Pierson JF, Marsh, CB, Allen JN, Pathak DS. Measurement of outcomes in adult-receiving pharmaceutical care in a comprehensive asthma outpatient clinic. Pharmacotherapy 1998;18:1365-74.
2. Munzenberger PJ, Vinuya RZ. Impact of an asthma program on the quality of life of children in an urban setting. Pharmacotherapy 2002;22:1055-62.
3. Stiegler KA, Yunker M, Crouch MA. Effect of pharmacist counseling in patients hospitalized with acute exacerbations of asthma. Am J Health-System Pharm 2003;60:433-6.
4. Anonymous. Physicians' desk reference, 58th ed. Montvale, NJ: Thomson PDR, 2004.
5. Devalia JL, Sapsford RJ, Rusznak C, Thoumbis RJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells in vitro. Pulm Pharmacol 1992;5:257-63.
6. Reid DW, Ward C, Wang N, et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J. 2003;21:994-9.
7. Jeffery PK, Venge P, Gizycki MJ, Egerod I, Dahl R, Faurschou P. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002;20:1378-85.
8. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids. JAMA 2001;285:2583-93.
9. 2-adrenoceptor on the development of tolerance to β-agonist. J Asthma 2000;37:691-700.
10. Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 2000;45:623-35.
11. Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery EM, Taylor DR. Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 2003;21:810-15.
12. 2-agonists in patients with chronic obstructive pulmonary disease. Chest 1990;97:280-4.
13. Repsher LH, Anderson JA, Bush RK. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984;85:34-8.
14. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial. Ann Intern Med 2000;132:97-104.
15. Cockcroft DW. Functional antagonism: tolerance produced by inhaled beta2-agonists. Thorax 1996;51:1051-6.
16. 2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999;103:1049-53.
17. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, for the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization global initiative for chronic obstructive lung disease (GOLD): executive summary. Respir Care 2001;46:798-825.
18. Kercsmar CM. Current trends in management of pediatric asthma. Respir Care 2003;48:194-208.
19. Walters EH, Walters JA, Gibson PW. Regular treatment with long-acting β-agonists versus daily regular treatment with short-acting β-agonists in adults and children with stable asthma. Cochrane Database Syst Rev 2002;4:CD003901.
20. Peters JI, Shelledy DC, Jones AP Jr, Lawson RW, Davis CP, LeGrand TS. A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. Chest 2000;118:313-20.
21. Pharma-Help.com. Salmeterol multi-center asthma research trial (SMART) information. Available from http://pharma-help. com/smart. Accessed January 15, 2004.
22. Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest 2002;121:1036-41.
23. Marik P, Hogan J, Krikorian J. A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Chest 1999;115:1653-7.
24. Rodrigo C, Rodrigo G. Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. Am J Emerg Med 1998;16:637-42.
25. Williams JR, Bothner JP, Swanton RD. Delivery of albuterol in a pediatric emergency department. Pediatr Emerg Care 1996;12:263-7.
26. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction: a meta-analysis. Arch Intern Med 1997;157:1736-44.
27. Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest 1996;110:42-7.
28. Reisner C, Kotch A, Dworkin G. Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. Ann Allergy Asthma Immunol 1995;75:41-7.
29. Besbes-Ouanes L, Nouira S, Elatrous S, Knani J, Boussarsar M, Abroug F. Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial. Ann Emerg Med 2000;36:198-203.
30. Rodrigo GJ, Rodrigo C. Continuous vs intermittent β-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002;122:160-5.
31. Hess DR, Acosta FL, Ritz RH, Kacmarek RM, Camargo CA. The effect of heliox on nebulizer function using a β-agonist bronchodilator. Chest 1999;115:184-9.
32. Kress JP, Noth I, Gehlbach BK, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Resp Crit Care Med 2002;165:1317-21.
33. Corcoran TE, Shortall BP, Kim IK, Meza MP, Chigier N. Aerosol drug delivery using heliox and nebulizer reservoirs: results from an MRI-based pediatric model. J Aerosol Med 2003;16:263-71.
34. Viau CJ, Kern T, Handley DA. Acute IV and oral toxicology of (S)-albuterol in rats. Presented at the American College of Allergy, Asthma, and Immunology annual meeting, Philadelphia, PA, November, 6, 1998.
35. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999;12:353-62.
36. Maier G, Henry A, Baumgartner RA, Rubino C, Cirincione B. The effect of the d-isomer, (S)-albuterol, is not through alteration of the pharmacokinetics of (R)-albuterol: a population PK analysis [abstr]. J Allergy Clin Immunol 2002;109:S237.
37. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615-21.
38. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102(6 pt 1):943-52.
39. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells in vitro. Pulm Pharmacol 1992;5:257-63.
40. + across the trachea of the dog in vitro. Am Rev Respir Dis 1979;120:547-52.
41. Sepracor Inc. Data on file. Study 051-516. Marlborough, MA; 2000.
42. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled β-adrenoreceptor agonists. Am J Respir Crit Care Med 2000;161:827-30.
43. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death from asthma. N Engl J Med 1992;326:501-6.
44. Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003;124:844-9.
45. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998;11:1-6.
46. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001;124:478-84.
47. Agrawal DK, Clark KC, Townley RG. Differential effects of albuterol enantiomers on pulmonary functions and bronchoalveolar lavage (BAL) eosinophilia [abstr]. Am J Respir Crit Care Med 2000;163:A590.
48. Davies J, MacIntyre N, Ahearn G, Hudson B, Webb B. A comparison of the use of levalbuterol compared to racemic albuterol in the pulmonary stepdown population [abstr]. Respir Care 2001;46:1083.
49. Carl JC, Myers TR, Kirchner L, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for the treatment of acute asthma. J Pediatr 2003;143:731-6.
50. Haider D. Breathing easier: highlighting new asthma medications. AARC Times 2000;Nov:38-42.
51. Ford D, Dilley S, Handley D. Levalbuterol use in the emergency department increases PEF over racemic albuterol [abstr]. Respir Care 2000;45(suppl):980.
52. Schreck DM, Brotea C, Shah SP. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma [abstr]. Ann Emerg Med 2001;38(pt 2). Available from http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action= searchDB&searchDBfor=art&artType=misc&id=jem384bab003025. Accessed January 15, 2004.
53. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004;22:29-36.
54. GlaxoSmithKline. Asthma in America, a landmark survey. Available from www.AsthmainAmerica.com. Accessed January 15, 2004.
55. White MV, Sander N. Asthma from the perspective of the patient. J Allergy Clin Immunol 1999;103:S47-52.